NeoGenomics shares are trading lower after the company announced new data from the Phase 3 PENELOPE-B study at the 2023 ASCO Annual Meeting.
Portfolio Pulse from Benzinga Newsdesk
NeoGenomics shares are trading lower after the company announced new data from the Phase 3 PENELOPE-B study at the 2023 ASCO Annual Meeting.

June 05, 2023 | 7:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NeoGenomics shares are trading lower after the company announced new data from the Phase 3 PENELOPE-B study at the 2023 ASCO Annual Meeting.
The announcement of new data from the Phase 3 PENELOPE-B study at the 2023 ASCO Annual Meeting has led to a decline in NeoGenomics' share price. This indicates that the market may have had higher expectations for the study results, or that the results may not have been as positive as anticipated. As a result, investors may be concerned about the company's future prospects, leading to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100